EcoDrugPlus

Nitric Oxide Synthase 2

Ensembl ID : ENSELUG00000001444
Gene Symbol: NOS2
1 Cross references
167 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSELUG00000016177
Gene Symbol: NOS2
3 Cross references
167 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2

Ensembl ID : ENSELUG00000023412
Gene Symbol: LOC105009095
3 Cross references
158 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2

Ensembl ID : ENSELUG00000023096
Gene Symbol: LOC105016232
3 Cross references
205 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSELUG00000004493
Gene Symbol: NFKB1
1 Cross references
202 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSELUG00000023685
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSELUG00000024344
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSELUG00000023409
Gene Symbol: NR3C1
4 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSELUG00000014053
Gene Symbol: NR3C2
3 Cross references
211 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSELUG00000006299
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSELUG00000011146
Gene Symbol: OPRD1
3 Cross references
195 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSELUG00000008032
Gene Symbol: OPRK1
4 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).